Thymosin beta 4 is unusual in this compound class for having controlled human data, RGN-259 ophthalmic solution has been assessed in randomised, placebo-controlled, double-masked Phase 2 and Phase 3 trials in severe dry eye and neurotrophic keratopathy (Sosne et al., Cornea 2015 and Int J Mol Sci 2023)
PubMed Central , Pharmaceuticals , vol
An orange a day keeps the doctor away: scurvy in the year 2000
We cannot guarantee that showing physicians this new leaflet Treatment is for Life -will get the patients injections reinstated straight away but we hope it will.
Targeted Wellness Combat oxidative stress, reduce inflammation, and strengthen your bodys defenses.
Low Starting Amount Amount per injection: 200 mcg 6 units (0.06 mL) on a U-100 insulin syringe Frequency: Once daily, under the skin (subcutaneous) Cycle length: 812 weeks Inject near the target site or in the abdomen